• Explore /
  • Poster
  • / A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).

A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).

Abstract Poster

Authors

null

Ana De Jesus-Acosta

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Ana De Jesus-Acosta , Peter J. O'Dwyer , Ramesh K. Ramanathan , Daniel D. Von Hoff , Anirban Maitra , Zeshaan Rasheed , Lei Zheng , N. V. Rajeshkumar , Dung T. Le , Antje Hoering , Vanessa Bolejack , Shinichi Yabuuchi , Daniel A. Laheru

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01088815

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr 257)

DOI

10.1200/jco.2014.32.3_suppl.257

Abstract #

257

Poster Bd #

B30

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.

Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.

First Author: Michele Reni

First Author: Philippa Corrie

First Author: Seng Wee Cheo

First Author: Emerson Yu-sheng Chen